Please read the following important notice and confirm your acceptance of the basis on which information is made available via this website:
The information to be provided is intended solely for use in the United Kingdom and the United States to inform institutional investors, eligible investors of a "qualified investor scheme" under FCA COBS 4.12.4 R and who also meets the criteria in COLL 8 Annex 2, or "accredited investors" (within the meaning of Regulation D under the U.S. Securities Act of 1933, as amended), and their advisers of a proposed investment fund, the Par Equity HealthTech Fund LP ("the Fund"), to be promoted in the United Kingdom and United States.
Par Fund Management Limited ("PFML") is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Par Equity Management (U.S) LLC, an affiliate of PFML, will, on establishment of the Fund, register with the United States Securities and Exchange Commission as advisor to the Fund. Par Equity (US) Management, LLC, and PFML are herein collectively referred to as Par Equity.
Par Equity does not provide advice on the suitability or appropriateness of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives. Investors should seek independent financial advice if they are in any doubt whether a product is suitable or appropriate for them.
Applications to invest in any fund or company referred to on this website or otherwise should only be made on the basis of the information set out in the relevant offering documentation. The investments referred to on this website are intended for experienced private investors and institutions and are not suitable for all investors.
The information on this website is directed only at persons in the UK and US and does not constitute advice of any kind (including investment or tax advice). It does not amount to an offer or invitation to buy or sell an investment in any fund or company referred to on this website.
